Olanzin (Olanzapine)

Olanzapine, the active ingredient in Olanzin, is an atypical antipsychotic presented as an oral tablet for oral use. It is prescribed for the management of schizophrenia and bipolar disorder, particularly manic episodes, in adult patients.

GNH USA supplies Olanzin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic used to treat major psychiatric conditions by modulating dopamine and serotonin pathways.

- Schizophrenia: reduces psychotic symptoms such as hallucinations, delusions, and thought disorder. - Bipolar disorder (manic episodes): stabilises mood and diminishes manic symptoms, helping prevent relapse.

Olanzapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Weight gain: increased appetite leading to gradual weight increase. - Sedation: drowsiness or feeling unusually sleepy. - Dry mouth: reduced salivation causing oral discomfort. - Constipation: slowed gastrointestinal motility. - Elevated triglycerides: changes in lipid metabolism. - Orthostatic hypotension: dizziness upon standing.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe reduction in white blood cells. - Hyperglycaemia/diabetes mellitus: significant rise in blood glucose levels. - Tardive dyskinesia: involuntary, repetitive movements. - Seizures: increased risk of convulsive episodes. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating Olanzapine, clinicians should consider several safety factors.

- Cardiovascular monitoring: assess blood pressure and heart rate regularly. - Metabolic screening: check fasting glucose, lipid profile, and weight at baseline and periodically. - CNS depression: avoid alcohol or other sedatives that may enhance drowsiness. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Elderly patients with dementia: increased risk of mortality; avoid unless clearly indicated. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Olanzapine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): may increase olanzapine plasma levels, raising toxicity risk. - CNS depressants (e.g., benzodiazepines, opioids): can potentiate sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce olanzapine concentrations, diminishing therapeutic effect. - Anticholinergic agents: may exacerbate dry mouth and constipation. - Antihypertensives: orthostatic hypotension may be enhanced. - Lithium: combined use may increase risk of neurotoxicity. - Antidiabetic drugs: monitor glucose as olanzapine can worsen hyperglycaemia.